S&P 500 Healthcare Sector SEC Filings — March 02, 2026
Across 35 filings in the USA S&P 500 Healthcare stream (with broader market exposure including biotechs, insurers, banks, and others), overarching themes include robust biotech pipeline advancements and financings (e.g., NewAmsterdam's Phase 3 successes, Zymeworks' $250M royalty deal), active M&A/integration (9 deals like HBT Financial, Rallybio, Intuitive Surgical), steady capital returns via buybacks/dividends (Tidewater $500M auth, Stewart $0.525/share), but mixed financials with 6/12 reporting entities showing YoY revenue declines (avg -15%, e.g., Core Scientific -16%, Zymeworks Q4 -92%). Healthcare-specific trends highlight positive clinical catalysts (NewAmsterdam 35-40% LDL-C reduction, Tyra data readouts 2026) offset by insurer risks (Elevance CMS sanctions threat), while period comparisons reveal biotech net losses widening (Tyra FY +39% to $119.9M) amid R&D ramps (+27-29% YoY). Insider activity mixed with sales at Coca-Cola Europacific ($1.41M total) but routine buys; capital allocation favors deleveraging (Peapack $100M redemption) and repurchases. Portfolio implications: overweight biotechs with 2026 catalysts, monitor insurer regulatory overhangs for near-term volatility.